Terry Harville
Concepts (104)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Common Variable Immunodeficiency | 2 | 2017 | 6 | 1.080 |
Why?
| Lung Diseases, Interstitial | 2 | 2017 | 23 | 1.050 |
Why?
| Isoantibodies | 4 | 2019 | 27 | 0.940 |
Why?
| HLA Antigens | 3 | 2019 | 52 | 0.850 |
Why?
| Autoantibodies | 1 | 2021 | 116 | 0.750 |
Why?
| Tissue Donors | 2 | 2019 | 111 | 0.700 |
Why?
| Graft Rejection | 2 | 2019 | 161 | 0.700 |
Why?
| Epitopes | 1 | 2019 | 59 | 0.640 |
Why?
| Blood Platelets | 2 | 2017 | 245 | 0.610 |
Why?
| Blood Grouping and Crossmatching | 1 | 2017 | 5 | 0.590 |
Why?
| Kidney Transplantation | 1 | 2019 | 175 | 0.560 |
Why?
| Decision Making | 1 | 2019 | 265 | 0.550 |
Why?
| Bronchiectasis | 1 | 2014 | 9 | 0.490 |
Why?
| Multiple Pulmonary Nodules | 1 | 2014 | 11 | 0.490 |
Why?
| Humans | 18 | 2022 | 49974 | 0.270 |
Why?
| Vaccination | 2 | 2022 | 266 | 0.270 |
Why?
| Blood Transfusion | 2 | 2017 | 121 | 0.260 |
Why?
| Immunologic Deficiency Syndromes | 2 | 2016 | 20 | 0.250 |
Why?
| Radiography | 2 | 2017 | 489 | 0.240 |
Why?
| Antibodies, Anti-Idiotypic | 1 | 2022 | 19 | 0.200 |
Why?
| Antibodies, Neutralizing | 1 | 2022 | 64 | 0.200 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2021 | 27 | 0.200 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2021 | 57 | 0.190 |
Why?
| Renin-Angiotensin System | 1 | 2021 | 58 | 0.190 |
Why?
| Hereditary Autoinflammatory Diseases | 1 | 2020 | 4 | 0.190 |
Why?
| Angiotensin II | 1 | 2021 | 157 | 0.180 |
Why?
| Immunologic Tests | 1 | 2019 | 6 | 0.180 |
Why?
| Fever | 1 | 2020 | 114 | 0.170 |
Why?
| Down Syndrome | 1 | 2020 | 91 | 0.170 |
Why?
| Male | 7 | 2021 | 25241 | 0.170 |
Why?
| Renal Insufficiency, Chronic | 1 | 2022 | 169 | 0.170 |
Why?
| Thrombosis | 1 | 2022 | 248 | 0.170 |
Why?
| Specimen Handling | 1 | 2019 | 55 | 0.170 |
Why?
| Antirheumatic Agents | 2 | 2008 | 35 | 0.150 |
Why?
| Preoperative Care | 1 | 2019 | 164 | 0.150 |
Why?
| Lymphoma, Follicular | 1 | 2017 | 27 | 0.150 |
Why?
| Histocompatibility Antigens Class I | 1 | 2017 | 44 | 0.140 |
Why?
| Fibrosis | 1 | 2017 | 179 | 0.140 |
Why?
| Immunoglobulins | 1 | 2016 | 79 | 0.140 |
Why?
| Immunoglobulins, Intravenous | 1 | 2016 | 54 | 0.140 |
Why?
| Antibodies | 1 | 2016 | 154 | 0.140 |
Why?
| Bone Marrow Transplantation | 1 | 2016 | 116 | 0.140 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 105 | 0.130 |
Why?
| Female | 6 | 2021 | 26472 | 0.130 |
Why?
| Flow Cytometry | 1 | 2016 | 476 | 0.120 |
Why?
| Lung | 1 | 2017 | 486 | 0.110 |
Why?
| Cardiomyopathy, Dilated | 1 | 2013 | 35 | 0.110 |
Why?
| Child | 4 | 2020 | 6847 | 0.110 |
Why?
| Heart-Assist Devices | 1 | 2013 | 148 | 0.100 |
Why?
| Proteasome Inhibitors | 1 | 2012 | 104 | 0.100 |
Why?
| Boronic Acids | 1 | 2012 | 182 | 0.090 |
Why?
| Pyrazines | 1 | 2012 | 187 | 0.090 |
Why?
| Retrospective Studies | 3 | 2017 | 6108 | 0.090 |
Why?
| alpha 1-Antitrypsin Deficiency | 1 | 2008 | 3 | 0.080 |
Why?
| Interleukin 1 Receptor Antagonist Protein | 1 | 2008 | 15 | 0.080 |
Why?
| Anemia, Hemolytic, Autoimmune | 1 | 2007 | 7 | 0.080 |
Why?
| Heart Transplantation | 1 | 2012 | 312 | 0.080 |
Why?
| Heart Failure | 1 | 2013 | 458 | 0.080 |
Why?
| Erythrocytes | 1 | 2007 | 83 | 0.070 |
Why?
| Evidence-Based Medicine | 2 | 2020 | 247 | 0.070 |
Why?
| Adult | 3 | 2020 | 13236 | 0.070 |
Why?
| Immunity, Humoral | 2 | 2016 | 22 | 0.060 |
Why?
| Antibodies, Monoclonal | 1 | 2007 | 459 | 0.060 |
Why?
| Aged | 1 | 2017 | 9310 | 0.060 |
Why?
| Injections, Subcutaneous | 2 | 2016 | 54 | 0.060 |
Why?
| Albuminuria | 1 | 2022 | 46 | 0.050 |
Why?
| Multiple Myeloma | 1 | 2017 | 2929 | 0.050 |
Why?
| Middle Aged | 1 | 2017 | 12069 | 0.050 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2022 | 172 | 0.050 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2022 | 388 | 0.050 |
Why?
| Diabetes Complications | 1 | 2020 | 118 | 0.040 |
Why?
| Cytokines | 1 | 2022 | 612 | 0.040 |
Why?
| Comorbidity | 1 | 2020 | 615 | 0.040 |
Why?
| Infant | 3 | 2013 | 3567 | 0.040 |
Why?
| Inflammation | 1 | 2022 | 604 | 0.040 |
Why?
| Mass Screening | 1 | 2020 | 353 | 0.040 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 2016 | 28 | 0.040 |
Why?
| Alzheimer Disease | 1 | 2020 | 324 | 0.040 |
Why?
| Immunomodulation | 1 | 2016 | 37 | 0.030 |
Why?
| Transplantation, Homologous | 1 | 2016 | 139 | 0.030 |
Why?
| Cardiovascular Diseases | 1 | 2020 | 440 | 0.030 |
Why?
| Practice Guidelines as Topic | 1 | 2016 | 449 | 0.030 |
Why?
| Haemophilus Vaccines | 1 | 2012 | 3 | 0.030 |
Why?
| Salmonella Vaccines | 1 | 2012 | 4 | 0.030 |
Why?
| Rabies Vaccines | 1 | 2012 | 4 | 0.030 |
Why?
| Bacteriophage phi X 174 | 1 | 2012 | 10 | 0.030 |
Why?
| Pneumococcal Vaccines | 1 | 2012 | 8 | 0.030 |
Why?
| Child, Preschool | 2 | 2013 | 3871 | 0.030 |
Why?
| Bacterial Capsules | 1 | 2012 | 18 | 0.030 |
Why?
| Obesity | 1 | 2020 | 1113 | 0.030 |
Why?
| Treatment Outcome | 2 | 2013 | 5141 | 0.020 |
Why?
| Cohort Studies | 1 | 2013 | 1422 | 0.020 |
Why?
| Blood Protein Electrophoresis | 1 | 2008 | 3 | 0.020 |
Why?
| Adolescent | 2 | 2012 | 6356 | 0.020 |
Why?
| Electrophoresis, Capillary | 1 | 2008 | 11 | 0.020 |
Why?
| Receptors, Interleukin-1 | 1 | 2008 | 17 | 0.020 |
Why?
| Protein Isoforms | 1 | 2008 | 119 | 0.020 |
Why?
| Disability Evaluation | 1 | 2008 | 87 | 0.020 |
Why?
| Immunoglobulin G | 1 | 2007 | 186 | 0.020 |
Why?
| Double-Blind Method | 1 | 2008 | 681 | 0.020 |
Why?
| Phenotype | 1 | 2008 | 729 | 0.020 |
Why?
| Disease Progression | 1 | 2008 | 825 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2008 | 1376 | 0.020 |
Why?
| Animals | 1 | 2016 | 13187 | 0.010 |
Why?
|
|
Harville's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|